BCR-ABL — Drug Target

All drugs that target BCR-ABL — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

BCR-ABL tyrosine kinase inhibitor · Tyrosine kinase inhibitor · BCR-ABL allosteric inhibitor

Marketed (1)

• Nilotinib 300 mg. · King Abdullah International Medical Research Center · BCR-ABL tyrosine kinase inhibitor · Oncology
  Nilotinib is a tyrosine kinase inhibitor that selectively blocks BCR-ABL and other kinases to inhibit abnormal cell proliferation in chronic myeloid leukemia.

Phase 3 pipeline (5)

• treatment of TKI in CML · Poitiers University Hospital · Tyrosine kinase inhibitor · Oncology
  This drug targets the BCR-ABL protein to inhibit cancer cell growth in chronic myeloid leukemia.
• Imatinib Mesylate and Nilotinib · University Hospital, Lille · Tyrosine kinase inhibitor · Oncology
  Imatinib and nilotinib are tyrosine kinase inhibitors that block BCR-ABL and other oncogenic kinases to suppress abnormal cell proliferation in chronic myeloid leukemia.
• Imatinib maintenance · Centre Leon Berard · Tyrosine kinase inhibitor · Oncology
  Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases to prevent cancer cell proliferation.
• Radotinib HCl · Il-Yang Pharm. Co., Ltd. · BCR-ABL tyrosine kinase inhibitor · Oncology
  Radotinib HCl is a BCR-ABL tyrosine kinase inhibitor designed to block the abnormal protein that causes chronic myeloid leukemia (CML).
• ABL001 · Marlise Luskin, MD · BCR-ABL allosteric inhibitor · Oncology
  ABL001 is an allosteric inhibitor of BCR-ABL that binds to a pocket distinct from the ATP-binding site, allowing it to overcome certain resistance mutations.